|Oliceridine (TRV130)||Phase 3||Mu-receptor||Moderate to
|TRV734||Phase 1||Mu-receptor||Moderate to
Oliceridine (TRV130) was designed to optimize opioid receptor pharmacology using Trevena’s ABLE™ platform and is intended to deliver an improved analgesic profile compared to conventional intravenous opioids. Oliceridine is the first μ-receptor G protein pathway selective modulator, or "μGPS", and is in development for the management of moderate-to-severe acute pain where intravenous therapy is preferred.
In February 2016, the FDA granted Breakthrough Therapy status to olicerdine. This designation is granted by the FDA to new therapies intended to treat serious conditions and for which preliminary clinical evidence indicates that the drug may demonstrate substantial clinical improvement over available therapies.
Copyright © Trevena, Inc.